NCT03265119View on ClinicalTrials.gov

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

September 24, 2018

Study Completion Date

October 1, 2018

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

AEVI-001

Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.

DRUG

Placebo

Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.

Trial Locations (1)

19087

Aevi Genomic Medicine, Wayne

All Listed Sponsors
lead

Aevi Genomic Medicine, LLC, a Cerecor company

INDUSTRY

NCT03265119 - PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations | Biotech Hunter | Biotech Hunter